Advertisement
top banner image  

topleft corner image     top right corner image
 
ACCF/AHA Clinical Guidelines and Statements

CME logo image
bullet
bullet
bullet
bullet

JACC Homepage JACC Imaging Homepage
Still not a subscriber to JACC Imaging or JACC Interventions?

take action
bullet
bullet
bullet
bullet
bullet
bullet
bullet
bullet

acc links
bullet
bullet
bullet
bullet
bullet
bullet
bullet
bullet
bullet

jacc interventions image
bullet
bullet
bullet
bullet

     top nav image

     

J Am Coll Cardiol Intv, 2009; 2:1095-1101, doi:10.1016/j.jcin.2009.08.018
© 2009 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gladding, P.
Right arrow Articles by Webster, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Gladding, P.
Right arrow Articles by Webster, M.
Related Collections
Right arrowRelated Article

Pharmacogenetic Testing for Clopidogrel Using the Rapid INFINITI Analyzer

A Dose-Escalation Study

Patrick Gladding, MBChB*,{ddagger},*, Harvey White, MBChB, DSc*, Jamie Voss, MBChB*, John Ormiston, MBChB*, Jim Stewart, MBChB*, Peter Ruygrok, MD, MBChB*, Badi Bvaldivia{dagger}, Ruth Baak, PhD{dagger}, Catherine White, MBChB*, Mark Webster, MBChB*

* Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
{dagger} AutoGenomics, Carlsbad, California
{ddagger} Theranostics Lab (NZ) Ltd., Auckland, New Zealand


Figure 1
View larger version (17K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 1 Baseline Platelet Inhibition

Platelet function demonstrated for each genotype group.

 

Figure 2
View larger version (29K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 2 Platelet Function at Baseline (75 mg) and 7 Days (150 mg)

Platelet function at baseline in patients on 75 mg once daily clopidogrel and after 1 week of 150 mg daily. Variable responses but overall a mean increase in platelet inhibition is demonstrated.

 

Figure 3
View larger version (20K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 3 Platelet Function in CYP2C19*2 Carriers at Baseline and 7 Days

Platelet function at baseline in CYP2C19*2 carriers and after 1 week of 150 mg daily clopidogrel. An improvement in platelet inhibition is seen in most patients.

 

Figure 4
View larger version (17K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 4 Change in Percentage Platelet Inhibition in CYP2C19*2 Carriers

Box plots represent median, range, and 25th and 75th quartiles. See text for discussion of poor metabolizer (PM) and intermediate metabolizer (IM) status.

 

Figure 5
View larger version (24K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 5 Change in Percentage Platelet Inhibition Over 1 Week in Patients on PPI

Increase in platelet inhibition after 1 week of 150 mg daily clopidogrel, in patients taking proton pump inhibitors (PPIs).

 

Figure 6
View larger version (20K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 6 Clopidogrel Response Incorporating Static and Variable Factors

CES = carboxylesterase; CVA = stroke; hPXR = human pregnane X receptor; IL = interleukin; TNF = tumor necrosis factor; T2DM = type II diabetes; wt = weight.

 




Advertisement
 
   
 
home link current link search link archive link topics link cardiology careers link